Charles River/$CRL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Charles River
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
- Ticker
- $CRL
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 19,000
- Headquarters
- Wilmington, United States
- Website
- www.criver.com
Charles River Metrics
BasicAdvanced
$18B
-
-$4.88
1.41
-
Price and volume
Market cap
$18B
Beta
1.41
52-week high
$379.63
52-week low
$146.20
Average daily volume
1.1M
Financial strength
Current ratio
1.348
Quick ratio
0.796
Long term debt to equity
1.048
Total debt to equity
1.048
Interest coverage (TTM)
5.29%
Profitability
EBITDA (TTM)
849.118
Gross margin (TTM)
35.81%
Net profit margin (TTM)
-5.96%
Operating margin (TTM)
12.40%
Effective tax rate (TTM)
-28.65%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
4.11%
Return on equity (TTM)
-7.52%
Valuation
Price to revenue (TTM)
4.594
Price to book
6.32
Price to tangible book (TTM)
-36.6
Price to free cash flow (TTM)
49.575
Free cash flow yield (TTM)
2.02%
Free cash flow per share (TTM)
7.587
Growth
Revenue change (TTM)
-0.74%
Earnings per share change (TTM)
255.12%
3-year revenue growth (CAGR)
-1.45%
10-year revenue growth (CAGR)
10.36%
3-year earnings per share growth (CAGR)
-19.73%
10-year earnings per share growth (CAGR)
5.13%
What the Analysts think about Charles River
Analyst ratings (Buy, Hold, Sell) for Charles River stock.
Analyst projections of the future price of Charles River stock.
Bulls say / Bears say
Demand is turning up in Discovery and Safety Assessment: its Q2 net book-to-bill ratio reached 1.19x, a nearly four-year high, and Charles River raised its 2026 organic revenue and earnings outlook. Stronger bookings offer a route to revenue growth as work moves through the backlog. (Reuters, Charles River Laboratories)
The efficiency plan could lift profitability: management targets more than $300 million in cumulative savings from 2027 to 2030 and a non-GAAP operating margin of about 24% by 2030. (Charles River Laboratories)
Bioanalysis offers a growth opportunity beyond the current recovery. Charles River expects the business to grow at a high-single-digit annual rate and reach about $450 million in revenue by 2030, while expanding lab capacity to serve demand. (Charles River Laboratories)
Research Models and Services remains weak: Q2 organic revenue fell 1.4%, and the company expects a low-to-mid single-digit decline for the year, citing lower North American model sales and constrained academic and government spending. (The Motley Fool)
Core profitability is still under pressure year on year: Q2 non-GAAP operating margin was 20.5%, down from 22.1%, as higher study costs in Discovery and Safety Assessment and higher corporate costs weighed on results. (Charles River Laboratories)
Chinese CROs are building more capabilities, while early-stage research has already shifted towards lower-cost markets. If Chinese providers extend further into regulated safety work, Charles River could face tougher competition for clients and pricing. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
Charles River Financial Performance
Revenues and expenses
Charles River Earnings Performance
Company profitability
Upcoming events
No upcoming events
Charles River News
AllArticlesVideos
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Business Wire1 week ago
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
Business Wire3 weeks ago
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
MarketBeat1 month ago
Funds containing Charles River
AllUSDEURGBP
Fund name | Fund size | $CRL weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.73% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.73% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.73% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.34% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.34% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.